Suppr超能文献

罗库溴铵诱导的神经肌肉阻滞在终末期肾病患者中的逆转:舒更葡糖钠的疗效和安全性:系统评价和荟萃分析。

Efficacy and Safety of Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis.

机构信息

Department of Anaesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Korea.

出版信息

Medicina (Kaunas). 2021 Nov 17;57(11):1259. doi: 10.3390/medicina57111259.

Abstract

Sugammadex is widely used in anesthesia to reverse rocuronium-induced neuromuscular blockade (NMB). In patients with compromised kidney function, most drugs show alteration of their pharmacokinetic profile with reduced clearance. The purpose of this article is to examine the efficacy, pharmacokinetics, and safety of sugammadex in end-stage renal disease (ESRD) patients receiving general anesthesia, using a systematic review. The databases of PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched for studies comparing the efficacy or safety outcomes of sugammadex administration for the reversal of rocuronium-induced NMB, in ESRD patients (group R) or in those with normal renal function (group N) undergoing surgery under general anesthesia. We identified nine studies with 655 patients-six prospective, case-control studies with 179 patients (89 and 90 in groups R and N) and three retrospective observational studies with 476 ESRD patients. In the six prospective studies, the times taken to reach a train-of-four ratio ≥0.9, 0.8, and 0.7 were significantly longer in group R than in group N (weighted mean difference [95% confidence interval] [min]: 1.14 [0.29 to 2.00], 0.9 [0.24 to 1.57], 0.89 [0.20 to 1.57], respectively). The total plasma clearance of sugammadex was significantly lower in group R than in group N. There was no significant difference in the incidence of NMB recurrence and prolonged time to recovery between the groups. In the three retrospective studies, the possibility of sugammadex-related adverse events appears to be insignificant. Sugammadex may effectively and safely reverse rocuronium-induced NMB in patients with ESRD, although the recovery to a TOF ratio of 0.9 may be prolonged compared to patients with normal renal function. Further studies are needed, considering the small number of studies included and the high heterogeneity of some of the results.

摘要

舒更葡糖钠广泛用于麻醉以逆转罗库溴铵引起的神经肌肉阻滞(NMB)。在肾功能受损的患者中,大多数药物的药代动力学特征发生改变,清除率降低。本文旨在通过系统评价,研究舒更葡糖钠在接受全身麻醉的终末期肾病(ESRD)患者中的疗效、药代动力学和安全性。检索PubMed、EMBASE、Cochrane 图书馆、Web of Science、Scopus、KoreaMed 和 ClinicalTrials.gov 数据库,以比较舒更葡糖钠用于逆转罗库溴铵引起的 NMB 的疗效或安全性结局的研究,研究对象为接受全身麻醉手术的 ESRD 患者(R 组)或肾功能正常的患者(N 组)。我们确定了九项研究,共纳入 655 例患者:六项前瞻性病例对照研究纳入 179 例患者(R 组和 N 组各 89 例和 90 例)和三项回顾性观察性研究纳入 476 例 ESRD 患者。在六项前瞻性研究中,R 组达到肌颤搐比值≥0.9、0.8 和 0.7 的时间明显长于 N 组(加权均数差值[95%置信区间][min]:1.14[0.29 至 2.00]、0.9[0.24 至 1.57]、0.89[0.20 至 1.57])。R 组的舒更葡糖钠总血浆清除率明显低于 N 组。两组之间 NMB 复发和恢复时间延长的发生率无显著差异。在三项回顾性研究中,舒更葡糖钠相关不良事件的可能性似乎并不显著。在 ESRD 患者中,舒更葡糖钠可能有效且安全地逆转罗库溴铵引起的 NMB,尽管与肾功能正常的患者相比,恢复至肌颤搐比值 0.9 的时间可能延长。考虑到纳入研究的数量较少且部分结果存在高度异质性,需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/218a/8622972/095817ac2fd9/medicina-57-01259-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验